Truist downgraded Longboard Pharmaceuticals to Hold from Buy with an unchanged price target of $60 after Lundbeck agreed to acquire the company for $60 per share.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Longboard Pharmaceuticals downgraded to Neutral from Outperform at Baird
- M&A News: Lundbeck to Acquire Longboard (NASDAQ:LBPH) for $2.6B
- Boeing to cut 10% of workforce, Lundbeck to acquire Longboard: Morning Buzz
- Longboard Pharmaceuticals downgraded to Neutral from Outperform at Wedbush
- Longboard Pharmaceuticals deal comes earlier than expected, says Truist